Opening Remarks, Metabolic Disease Prevention



welcome i hope foes with as people draco in we kick off this symposium first public symposium sponsored by the blog welcome fun my name is Simon lil I am a professor of Epidemiology at the public health school here and co-director of this new program that this new inter school program in metabolic disease now the idea of this program is basically trying to bring everybody together across the entire UCLA campers with expertise and experience in pretty much all facets of metabolic disease related research and most of view in this room would be aware of the really ongoing epidemics of obesity and diabetes worldwide and we is recognizing these very troubling trends currently happening that the campers why leadership come together and establish these interdisciplinary programs and and with the hopes that to integrate and take advantage of the autism major advances in medical science to come to adjust the mom this emerging epidemic so this is the first symposium and it's a kickoff of this program so that we would attract Chinese with the ability as well as ambition to pursue this lack of research and again welcome with that I would be my Tom co-director to say a few words so likewise welcome I'm Tom Drake I'm a professor in the department of pathology and laboratory medicine along with the chair i'm making a stab at sort of enlarging the scope of what pathology typically does which has been fun and leads in a lot of different directions and to complement what semaine just said about the purpose of the program burroughs wellcome fund has has supported several traineeships for to develop individuals into researchers where they foresee will really be where science is happening and people are not being prepared for with just the usual classical approaches in in PhD training and for those of you who've been involved in interdisciplinary work I change is hard nothing comes easy and even things that should be simple aren't and the concept is that this particular sphere that they focused on really needs to have some set of people at least have a broader experience in their training than what they would get just by going through the regular program here and so the essence of this and why it's called the inter-school program is it essentially people who enter it and which we hope to facilitate in terms of interactions among faculty are to be exposed and to really have an understanding of epidemiologic principles and the science behind it as well as as the more basic and intermediate levels of science that that the majority of people i'd have to say here UCLA do at least on the medical school side so we before our keynote speaker begins we have the deans of both schools here who kindly came to say a few words of encouragement to us and to everybody else so let me introduce dr. Alan Robinson who appropriately is an endocrinologist by bike so that's that's good he's the associate vice chancellor for medical sciences as well as the executive associate dean and he's been very supportive and assisted us in a number of ways to get the program off the ground Alan thank you well I add my welcome yes I am I a man under college' so like many of you in this room i have watched with alarm the increasing prevalence of diabetes and obesity in our population indeed if you looked at the LA Times this morning you saw there's an entire section devoted to diabetes and obesity and and its effect on on our population say go back a decade ago when we were all very interested in the human genome and I had the expectation naively it turns out now that we would once we mapped the human genome that we would find the gene that was responsible for type 2 diabetes and we would develop one or two pharmacologic therapies that would be widely applicable to the population turns out that isn't true at all there are a bunch of little genetic variations that contribute to the onset of diabetes and they all interact with with that person's metabolic profile which is probably a part of their ethnic genetic background and those two things then interact with the environment which we're just beginning to to even think about understanding so this kind of a program i think is is really critical to training people who think this way i thought again i thought one time that that personalized medicine would be a few pharmacologic interventions based on as I said that would be wild widely available now I think that the personalized interventions are going to be a lot of different different pharmacologic agents that are only targeted to a small number of people the widely available things will be those things those findings that grow out of the ethnic population that grow out of our relationship with the environment I believe those are the things that are going to be widely available in approaching these problems and I don't think that there is any place better in the world to study these things that in UCLA than it use the OA we have it I honestly think it's in our bones to do interdisciplinary research and we have an outstanding school of public health we have an outstanding school of medicine and we are located in Los Angeles where these ethnic we where we have this diversity of ethnic populations that are a part of our clinical populations and that are available for us to to learn from and to learn about so I I congratulate dr. Liu and dr. Drake on taking advantage of this borough burroughs welcomes fund for organizing this program for organizing this symposium I think that the program will be wildly successful because it's critical that we train that kind of investigator that that you imagine so thank you for doing it for our school and now I have a distinct personal pressure to introduce our Dean at the School of Public Health Linda cotton in the rosenstock thank you well thanks and good morning everybody turns out Alan and I have similar reading habits in the morning I actually knowing how remarkably productive and successful that doctors Drake and lo have been thought they must have planned today's weekly health science section devoted to diabetes but it's certainly a timely a topic and I just want to add my welcome from the School of Public Health and from UCLA for this terrific effort you know it for the Burroughs Wellcome funding which has been in place for about a year and the Center for metabolic diseases about the same time there's already such obvious productivity in terms of training activities in terms of research productivities with major articles coming out in major journals this symposium inviting my former colleague from the University of Washington another coup it's a pleasure to be back here with dr. Prentiss and I know there's a phenomenal day set out ahead of you just want to echo the the public health side of dr. Robinson's comments because I know you're going to be dealing with statistics and a lot of cutting edge technology but as we do look at this epidemic and and of course we know what it means in the United States and we know what it means globally in terms of numbers read review sort of surprised me about we always think we are the tip of the iceberg in the United States of this phenomenal epidemic and of course we know we're not alone but if you look projecting the growth rates of obesity and in turn diabetes around the world we're going to be dwarfed soon in terms of rates of growth as other developing countries start with larger populations than we have to actually multiply their risks so like much else we're doing in health it is global and the combination of both public health and medical interventions and technologies will probably be the most powerful way we can attack it rather than naively see I naively thought we just kept Public Health stop all these problems and you thought all personalized medicine but in fact as always we know it's some combination of the two as as we move forward a number some of you may have missed from the Centers for Disease Control and Prevention that was published in the last few months was trying to assess the economic burden of obesity in the US alone it's roughly 150 billion dollars a year which rivals cancer so it is not just enormous human cost of which you're all aware but its enormous economic constant it's hard again not to think of this being at the moment given our discussions in the US about health care reform about the need to control costs and tackle things in a better way and hard to imagine a better area of intervention than this one of metabolic diseases so again congratulations to our co-directors for everything they've done and for everything they're going to be doing in the years to come pleased to be here to welcome

Leave a Reply

Your email address will not be published. Required fields are marked *